Quiz Ref ID Dual antiplatelet therapy with the combination of clopidogrel and aspirin was shown to reduce the early risk of new stroke in patients with minor ischemic stroke or transient ischemic attack (TIA) in a Chinese population enrolled in the Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) trial.
1 The efficacy of dual antiplatelet therapy was further validated in North America, Europe, Australia, and New Zealand in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial.
2 However, an increase in major hemorrhage observed in the POINT trial led to concerns about bleeding risks in dual antiplatelet therapy.
3 Uncertainties remained about the risks and benefits of dual antiplatelet therapy and the optimal duration of dual antiplatelet therapy for minor stroke or TIA. Moreover, the 2 trials were each moderate in size, whereas pooled-data analysis can provide more precise estimates of treatment outcomes. As the investigators from the CHANCE and POINT trials, we sought to address these questions about the risks and benefits of dual antiplatelet therapy after minor ischemic stroke or TIA by analyzing pooled individual patient–level data from the 2 trials.